BMS makes quickfire bets on neurodegeneration, paying $95M to exercise Evotec, Prothena options

Bristol Myers Squibb has pulled the trigger on two neuroscience options, paying Prothena $55 million for a global license to a clinical-phase Alzheimer’s disease drug candidate and handing Evotec $40 million for rights to certain late-stage discovery programs.